Hologic INCHOLX
Health Care · Health Care Equipment
$76.03
+0.50%
Vol: 77.5M
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours; Hologic was taken private by Blackstone and TPG in April 2026 and is delisted.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Hologic completed its $18B+ go-private acquisition by Blackstone and TPG; shares have been delisted and the company received FDA approval for its Aptima HPV primary screening assay.Mixed▶
Hologic's previously announced take-private deal with Blackstone and TPG closed in early April 2026 at $76 per share in cash plus a contingent right to up to $3 per share tied to global revenue goals, with the common stock now delisted. Long-time chairman and CEO Steve MacMillan retired at close, and Jose Almeida was appointed CEO. Separately, the FDA approved Hologic's Aptima HPV Assay for clinician-collected HPV primary screening, the only FDA-approved mRNA-based HPV test. As of mid-May 2026, HOLX is no longer publicly traded, so day-to-day stock news is limited to wind-down and post-close items. Risk: legacy public shareholders no longer have exposure; remaining contingent value depends on hitting revenue milestones.
May 20Hologic taken private by Blackstone and TPG for up to $79/share, Jose Almeida named CEO and shares delistedPositive▶
Hologic completed its go-private acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $18.3B (up to $79/share), with shareholders receiving $76 cash plus a non-tradable CVR of up to $3 tied to Breast Health revenue goals. Jose E. Almeida, former Chairman, President and CEO of Baxter International, was appointed CEO effective immediately, succeeding long-time CEO Steve MacMillan who retired upon closing. Common stock has ceased trading at $76.01 and is being delisted from Nasdaq. The deal was originally announced October 21, 2025 and approved by shareholders February 5, 2026. Bear case: public-market investors no longer have access to the equity, and the CVR upside depends on hitting specified Breast Health revenue milestones that may or may not materialize.
May 19Hologic completes $18.3B go-private deal with Blackstone/TPG; CEO Steve MacMillan retires, succeeded by Jose AlmeidaNeutral▶
Hologic finalized its take-private transaction with Blackstone and TPG at up to $79 per share ($76 cash + CVR of up to $3 tied to Breast Health revenue goals), valuing the company at roughly $18.3 billion. Steve MacMillan retired as Chairman, President and CEO after more than 12 years at the helm, with Jose Almeida appointed as successor. Public market upside is limited near the $76 buyout price and the company is no longer publicly traded post-close. The deal had previously been announced in October 2025 and approved in February 2026. This concludes a major medtech consolidation and removes HOLX from public indices.
May 18Hologic completed go-private acquisition by Blackstone and TPG for up to $79/share, delisting from public marketsPositive▶
Hologic completed its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, taking the company private. Stockholders received $76 per share in cash plus a non-tradable contingent value right of up to $3 per share tied to Breast Health revenue goals in fiscal years 2026 and 2027. The total deal value was approximately $18.3 billion. CEO Steve MacMillan retired upon closing, with Jose E. Almeida appointed as the new CEO. Hologic's Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening, the only FDA-approved mRNA-based assay. The stock has been delisted from public trading.
May 15Hologic joins S&P SmallCap 600 May 14 following $18.3B Blackstone/TPG go-private acquisitionNeutral▶
Hologic joined the S&P SmallCap 600 index effective May 14, 2026, following its April 7 acquisition by Blackstone and TPG affiliates at $76 per share in cash plus contingent value rights (CVR) of up to $3 per share based on Breast Health revenue targets. The $18.3 billion go-private transaction marks the company's transition out of large-cap public ownership. CEO Steve MacMillan retired upon close of transaction, succeeded by José Almeida. Hologic previously received FDA approval for its Aptima HPV Assay primary screening option in February. The Envision Mammography Platform with 2.5-second scan time is set for commercial launch. Risk: post-acquisition strategic execution under PE ownership.
May 14Hologic completed go-private acquisition by Blackstone and TPG; no significant news in last 48 hours.Neutral▶
No material news in the last 48 hours. The major corporate event was Hologic's completion of acquisition by Blackstone and TPG for up to $79 per share on April 7, 2026, which took the company private with Jose E. Almeida named as new CEO succeeding Steve MacMillan.
May 13Hologic completed go-private acquisition by Blackstone and TPG for up to $18.3B; CEO MacMillan retired and Jose Almeida named new CEO at deal close.Mixed▶
On April 7, 2026, Blackstone and TPG completed their acquisition of Hologic, with shareholders receiving $76 per share in cash plus a non-tradable CVR worth up to $3 per share (total up to $79). Stephen P. MacMillan and the prior board resigned, with Jose E. Almeida appointed CEO. The deal involves redeeming $400 million of 4.625% notes due 2028 and $950 million of 3.250% notes due 2029, and terminating a long-standing credit agreement. Hologic shares have been delisted from Nasdaq as the company moves off public markets. The transition simplifies the legacy capital structure as the medtech firm operates as a private entity. Risk: any remaining minority/dissenting shareholder litigation and CVR milestones uncertainty.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 11No significant overnight updatesNeutral▶
Hologic was taken private by Blackstone and TPG in a $18.3B transaction completed April 7, 2026; shares were delisted from Nasdaq and no material news has been reported for May 4-11, 2026.
May 8No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 7Blackstone/TPG acquisition closes April 7 at $79/share; Jose Almeida named CEO; FDA approves Aptima HPV screeningNeutral▶
Hologic completed go-private acquisition by Blackstone and TPG on April 7, 2026, at up to $79/share ($76 cash plus $3 contingent value right). All regulatory approvals received; company now private. Jose Almeida appointed Chief Executive Officer effective immediately, succeeding retiring Steve MacMillan. Q1 FY2026 revenue of $1,047.8M up 2.5% (1.3% constant currency). FDA approved Aptima HPV Assay for clinician-collected primary HPV screening on Feb 4 - only FDA-approved mRNA-based HPV assay. Shareholders approved merger with 178.8M votes for, 151K against. Analyst consensus holds: median PT $78.36.
May 6Hologic acquisition by Blackstone/TPG closes at $76 cash per share plus $3 CVR; José Almeida named CEOPositive▶
Hologic's acquisition by Blackstone and TPG closed at $76.00 per share in cash plus one contingent value right (CVR) potentially worth up to $3.00 based on future Breast Health revenue milestones. The company transitioned to private ownership with José Almeida appointed CEO (ex-Baxter) replacing retiring Steve MacMillan. Q1 FY2026 revenue was $1,047.8M (up 2.5%, +1.3% constant currency) with non-GAAP diluted EPS of $1.04 (up 1.0%) and strong cash flow from operations growth of 21.4%. The FDA approved Aptima HPV Assay for clinician-collected HPV primary screening on February 4, 2026, offering comparable sensitivity to DNA tests. The stock reached a 52-week high of $76.04 reflecting deal certainty and operational momentum under new leadership. Private ownership enables strategic flexibility for portfolio optimization and margin improvement.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABTABBOTT | $88.64 | +0.16% | +0.0% | 14.6x | 0.62 | $154.0B |
| ISRGINTUITIVE | $406.90 | +1.17% | -9.4% | 34.5x | 1.45 | $144.1B |
| SYKSTRYKER | $309.23 | +2.68% | -4.3% | 18.4x | 0.79 | $118.0B |
| MDTMEDTRONIC | $79.43 | +1.64% | +1.5% | 12.4x | 0.60 | $101.9B |
| BSXBOSTON | $45.25 | +0.66% | -20.1% | 12.2x | 0.56 | $67.3B |
Key Fundamentals
RSI (14-Day)
Moving Averages
Price above both MAs — bullish structure.